Brief: Quantum Genomics To Present Results From Phase III FRESH Study On Hypertension On Nov 4

Quantum Genomics SA

19/09/2022 06:38

Sept 19 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * QUANTUM GENOMICS ANNOUNCES THAT IT WILL PRESENT THE
RESULTS FROM
ITS PHASE III FRESH STUDY ON DIFFICULT-TO-TREAT AND RESISTANT
HYPERTENSION AT THE ANNUAL AMERICAN HEART ASSOCIATION (AHA)
CONFERENCE ON NOVEMBER 4 , 2022
    * 515 ELIGIBLE PATIENTS WITH DIFFICULT-TO-TREAT OR RESISTANT
HYPERTENSION WERE RANDOMISED IN STUDY IN 69 HOSPITALS ACROSS
EUROPE, CANADA, UNITED STATES AND LATIN AMERICA
    * RECRUITMENT FOR REFRESH STUDY, SECOND PIVOTAL PHASE III
STUDY TO
ACCESS EFFICACY AND LONG-TERM SAFETY OF ONCE DAILY FORMULATION
OF FIRIBASTAT, IS CONTINUING NORMALLY

Source text for Eikon:  ID:nACT76243 
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))